Bone and Soft Tissue Response in Bone-Level Implants Restored with Platform Switching: A 5-Year Clinical Prospective Study

2017 ◽  
Vol 32 (4) ◽  
pp. 919-926 ◽  
Author(s):  
Laura Lago ◽  
Luis da Silva ◽  
Francisco Gude ◽  
Benito Rilo
2018 ◽  
Vol 1 (4) ◽  
pp. 327-330
Author(s):  
Sergio Olate ◽  
Márcio De Moraes ◽  
Celso Palmieri

Orthognatic and orthofacial surgery contains procedures designed to correct skeletal facial anomalies, presenting clear aesthetic and functional orientations. Outcomes have demonstrated that the technique is efficient in the short and long terms; nowadays, orthognatic surgery is common in facial surgical practice. Nevertheless, the aesthetic aspects of the indication and results of the surgery make accurate planning a challenge, raising doubts in terms of recognizing the real soft tissue response to the movement produced at bone level. A prospective, multicenter study will be necessary to define this clinical situation? This brief review is an example of how necessary to study new methodologies about the response of soft tissue to bone movements.


Kidney Cancer ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 151-158
Author(s):  
Katherine Yuxi Tai ◽  
Jad M. El Abiad ◽  
Carol D. Morris ◽  
Mark Christopher Markowski ◽  
Adam S. Levin

BACKGROUND: Checkpoint inhibitors and receptor tyrosine kinase inhibitors (RTKIs) have changed the standard of care for metastatic renal cell carcinoma (mRCC). Anecdotal evidence suggests these therapies may be less effective for treating bone than soft-tissue metastases. PURPOSE: We performed a retrospective review evaluating the relative clinical responses in soft-tissue and bone metastases in patients undergoing therapy using RTKIs and anti-programmed death-1 (PD-1) agents for mRCC. METHODS: Of the 2,212 patients in our institutional cancer registry with renal cell carcinoma (1997–2017), 68 (82 disease courses) were identified with measurable bone and soft-tissue metastases treated with RTKIs and/or PD-1s. Extent of metastasis was quantified at the time of therapy initiation (baseline) and at 3 months, 6 months, and 1 year. Changes in disease status were categorized as complete response, partial response, stable, mixed, or progression of disease according to RECIST v1.1 and MD Anderson criteria. These categories were further organized into “response to treatment” or “evidence of progression” to generate a generalized linear effects model with soft-tissue response as the independent variable and bone response as the dependent variable. Alpha = 0.05. RESULTS: Soft-tissue response correlated with bone response at 3 months (76 disease courses, p = 0.005) and 6 months (48 disease courses, p = 0.017). Of the patients with controlled soft-tissue disease, only 14 (19%) and 15 (32%) had progression in bone at 3 and 6 months, respectively. CONCLUSION: Contrary to anecdotal reports, osseous metastases do not appear to respond worse than soft-tissue metastases to treatment with these agents.


2014 ◽  
Vol 25 (4) ◽  
pp. 1383-1388 ◽  
Author(s):  
Sameh Ahemd Seifeldin ◽  
Maha Shawky ◽  
Saleem M. Hicham Nouman

2016 ◽  
Vol 32 (4) ◽  
pp. 263-273
Author(s):  
Young-Hoon Lee ◽  
Kyung-Ho Ko ◽  
Yoon-Hyuk Huh ◽  
Chan-Jin Park ◽  
Lee-Ra Cho

Sign in / Sign up

Export Citation Format

Share Document